Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer

This study has been terminated.
(no additional funding)
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00574236
First received: December 13, 2007
Last updated: January 16, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2009
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)